pragma.vision Your technology observatory

Verification register Bio, Health & Neuro

Readiness verdict

Tarlatamab (Imdelltra) DLL3 bispecific

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-06-28
Revision
1
Method
v1.0.0

Current reading

The readiness gap, in one scan

AI-assisted assembly · derived results

Claimed
95

Public ambition and stated capability

Reported
93

Observed practitioner reporting

Verified
86

Independently supported evidence

Gap
+9

Claimed minus verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-06-28

Adopt with guardrails

Why
Fully FDA-approved with a Phase 3 OS win (13.6 vs 8.3 mo, HR 0.60) and traditional-approval maturity, but the boxed-warning CRS/ICANS profile plus an inpatient step-up regimen is a hard operational guardrail, reinforced by real-world ICANS exceeding trial rates.
Next
Track real-world CRS/ICANS management data and community-site uptake post full-approval; model the DLL3xCD3 bispecific pattern as a reference for T-cell engager monitoring requirements

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
7
Tier 1
0
Tier 2
3
Tier 3
4
Supports
3
Contradicts
1
Context
3
Latest observed
2025-11-30

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

This is the initial public reading. No earlier readiness change is recorded.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.